Clinical Trial Update: A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is investigating corneal endothelial cell changes in participants with neovascular age-related macular degeneration treated with the Po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Neovascular Age-related Macular Degeneration | Phase 4 | Status: RECRUITING